How Dublin Keeps Big Pharma Happy “It’s moving from basic manufacturing to sophisticated R&D to fend off rivals”

The Trials of ImClone “A founder in handcuffs, financials in disarray, and a vital product in doubt-for CEO Daniel Lynch,

The Time Is Right for These Seven Biotechs “In most years, biotechs decline in the spring as investors anticipate a

Biotech Knockoffs Lure Novartis “A big pharma player is expanding its generics business. Expect others to follow The divide between

Biotech returning to favor “After a nearly four-year slowdown, money is beginning to flow again into the biotechnology sector. But

Drug firms in United States, Europe move biotech work to India “Drug makers in the United States and Europe are

Singapore Wants You! “The future-friendly city-state has an offer bioscientists can’t refuse: unrestricted research, top-notch equipment, and limitless funds. (Just

Biotech’s Longer Convalescence “The biotech sector has fallen, and it doesn’t seem able to get up. “

Biotech’s Longer Convalescence “The biotech sector has fallen, and it doesn’t seem able to get up. “

China: how to seize “commanding point” of biotechnology “China’s capital investment in the scientific research of life science is far